<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">


MALDI-ToF mass spectrometry

Top-down proteomics approach for analyzing intact proteins in serum.

DeepMALDI® Overview

We use high density matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry technology to broadly interrogate the proteome — including post-translational modifications and splice variants — without the need to identify specific protein biomarkers in advance.

We have developed a proprietary technology, the DeepMALDI® system, as a method to overcome some of the limitations of conventional MALDI-ToF and other mass spectrometry methods to produce highly sensitive, stable, and reproducible data best suited for discovery of biomarkers with clinical utility.

Key Benefits of DeepMALDI® Analysis

bdx-tube-icon Minimal Sample Input - as little as 20 μL of serum or plasma
bdx-check-icon High Likelihood of Proteomic Signature Discovery
bdx-multiplex-icon Highly Multiplexed & High Throughput
bdx-icon-differentiators-15 Differentiates Splice Variants & PTMs
bdx-target-icon Robust &
bdx-doctor-icon Established Clinical Dx Testing

Host Biology: The Circulating Proteome

We develop multivariate proteomic tests that can measure protein abundance to gain a real-time comprehensive view of a patient’s immune profile and changing disease state. Blood-based proteomic analyses reflect innate or adaptive immune responses that may affect clinical outcomes on immunotherapy and other treatments.

Mass Spectrometry

Taking a biologically agnostic snapshot of the circulating proteome using Deep MALDI® mass spectrometry.

Machine Learning Test Design

Converting the acquired molecular data into a clinical test using modern machine learning.

Our test design approach

Biological Mechanism

Interpreting the host’s biology using multiple assessment methods, such as LC-MS and biological pathway protein set scoring.

The VeriStrat®​ Test

  • Multivariate test that identifies the chronic elevation of acute phase reactants
  • Profiles both acute and chronic inflammatory states, which are known to be associated with aggressive cancer
  • Impacts treatment strategy and facilitates disease state monitoring
  • Clinically available and reimbursed for over 210 million lives in the U.S.
Learn more about Veristrat

ImmunoStrat®​ Protein Signatures​

The ImmunoStrat® suite of protein signatures have been designed to interrogate a patient’s circulating proteome with the goal of predicting response to various immunotherapies across multiple tumor types.

Lung Cancer Risk of Recurrence Test

  • We have designed a pre-treatment serum protein signature that can identify stage I non-small cell lung cancer patients who have a high-risk of recurrence post-curative resection and may benefit from the addition of adjuvant therapy.
  • This test is currently for research use only.

Biological Pathway Protein Set Scoring

  • We have adapted the well-established methods of gene set enrichment analysis (GSEA) to understand protein pathways that are associated with different protein signature test results. ​
  • Pathways include: glycolytic processes, complement system, acute response, wound healing, interleukin-10 and immune response type II.

Custom Signature Discovery​

  • We design custom protein signatures with machine learning to support our partners drug development programs.
  • These tests are designed to help answer specific clinical questions, including selecting patients for immunotherapies, novel therapy combinations, or alternative treatment pathways.
Learn more about our test design process

Get in touch

Contact Us

What we do

Learn More

Data library

Discover More

Interested in another topic?